Page 59 - TD-1-1

Tumor Discovery

CASE REPORT
Combined anti-PD1 immunotherapy for patient

with advanced pancreatic cancer: A case report

Zhe Jiang, Hongyan Li*, and Fei Li
Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China

Abstract

Pancreatic cancer (PC) is a highly lethal malignancy with a dismal 5-year survival
rate. The current treatment modalities for the treatment-associated toxicity of
immunotherapy-based approaches are limited. Immunotherapy for PC was needed
to be further investigated. This report illustrates the combined use of anti PD-1
immunotherapy with other therapeutic strategies for cancer pain. In this case,
a patient with PC was treated with surgical resection, chemotherapy, molecular
targeted medicine, and anti-PD1 immunotherapy. The survival period of the patient
was more than 6 years since diagnosis. Finally, we will present our perspective on the
future development of immunotherapy for PC. In a word, this case report sheds lights
on information that would be helpful for more rigorous exploration of PC treatments.

Keywords: Pancreatic cancer; Immunotherapy; PD1

1. Background
[1]
*Corresponding author: Pancreatic cancer (PC) leads to an estimated 227,000 deaths per year worldwide . Only
Hongyan Li about 4% of patients can survive 5 years after diagnosis. Nowadays, surgical resection is
(hongyanli09@126.com) the mainstay of the treatment for PC . However, 80–85% of patients are presented with
[2]
[3]
Citation: Jiang Z, Li H, Li F, 2022, advanced unresectable disease . Adjuvant treatment is recommended for individuals
Combined anti-PD1 immunotherapy who undergo pancreatic resection with curative intent.
for patient with advanced pancreatic
cancer: A case report. Tumor Chemotherapy is the mainstay of the treatment for individuals with advanced
Discov, 1(1): 52. [4]
https://doi.org/10.36922/td.v1i1.52 disease . Gemcitabine is standard for patients with advanced PC; it induces a partial
response in a few people and can alleviate symptoms to some extent with advanced
Received: March 16, 2022 tumors.
Accepted: April 29, 2022
Published Online: May 6, 2022 Fractionated radiation therapy is typically delivered with fluorouracil or capecitabine,
Copyright: © 2022 Author(s). an oral fluoropyrimidine that acts as a radiosensitizer. Different types of radiation
This is an Open Access article therapy, such as intensity-modulated radiation therapy and stereotactic body radiation
distributed under the terms of the
Creative Commons Attribution therapy, enable dose escalation and sparing of healthy tissues that could improve tumor
License, permitting distribution, control with tolerable side effects, but these modalities need further assessment in
and reproduction in any medium, prospective clinical trials .
[5]
provided the original work is
properly cited. The most important pathways include those targeted for genetic and epigenetic
Publisher’s Note: AccScience alterations, that is, those that include protein products of KRAS, RB1 and CDKN2A,
Publishing remains neutral with TP53, and SMAD4 and TGFB1 genes . Germline mutations in BRCA2, PALB2,
[6]
regard to jurisdictional claims in CDKN2A, STK11, and PRSS1 genes, and Lynch syndrome, are associated with a
published maps and institutional
affiliations. substantially increased risk of PC. In Phase III clinical trials, the combination of

Volume 1 Issue 1 (2022) 1 https://doi.org/10.36922/td.v1i1.52